中国药物经济学2024，Vol.19Issue(10)：30-34,5.DOI:10.12010/j.issn.1673-5846.2024.10.004
曲妥珠单抗双规格(150mg+60mg)组合治疗人表皮生长因子受体2阳性乳腺癌的临床综合评价
Clinical Comprehensive Evaluation of Two Specifications Trastuzumab(150 mg+60 mg)Combination in the Treatment of HER2-positive Breast Cancer
邹杰 1黄洁莹 1王丽娜 1李雯婷 1徐伟1
作者信息
- 1. 中国药科大学国际医药商学院,南京 211198
- 折叠
摘要
Abstract
Objective To analyze and evaluate the Clinical comprehensive evaluation of two specifications trastuzumab(150 mg+60 mg)combination in the treatment of HER2-positive breast cancer.Methods Literature research and expert consultation methods were used to construct a comprehensive clinical evaluation framework and indicators,and combined with systematic reviews,clinical trial data,real-world studies,drug instructions and other information,a qualitative and quantitative approach was used to analyze the two specifications trastuzumab(150 mg+60 mg)combination of effectiveness,safety,economy,suitability,accessibility and innovation.Results The results of various clinical trials show that trastuzumab biosimilars have similar safety and effectiveness to the trastuzumab.Due to the late launch of trastuzumab 150 mg and 60 mg,their availability is poor.The cycle treatment costs of trastuzumab 150 mg and 440 mg alone without any remaining fluid are 77,648 yuan and 82,500 yuan respectively.The cost of two specifications trastuzumab combination is 64,869.34 yuan,which is more economical.In terms of affordability,combination of two specifications of trastuzumab＞trastuzumab storage＞HLX02(150 mg)＞trastuzumab waste;and the use of dual-strength combination has certain limitations Clinical use innovation.Conclusion The combination of two specifications of trastuzumab(150 mg+60 mg)has good clinical value and can provide relevant reference for rational clinical drug use and selection of relevant national drug catalogs.关键词
曲妥珠单抗/乳腺癌/生物类似药/临床综合评价/临床价值Key words
Trastuzumab/Breast cancer/Biosimilars/Clinical comprehensive evaluation/Clinical value分类
医药卫生引用本文复制引用
邹杰,黄洁莹,王丽娜,李雯婷,徐伟..曲妥珠单抗双规格(150mg+60mg)组合治疗人表皮生长因子受体2阳性乳腺癌的临床综合评价[J].中国药物经济学,2024,19(10):30-34,5.
